GRIP Molecular Technologies, Inc

I'm happy to announce that my paper titled "Graphene Multiplexed Sensor for Point-of-Need Viral Wastewater-Based Epidemiology" was recently published in ACS Applied Bio Materials! Thank you to all co-authors for your hard work.

Excited to announce our new publication demonstrating that our #graphene based #biosensor can detect viruses in #wastewater better than mass-spec! Towards a new era in #epidemiology, it's fabricated on a whole wafer! Great work by Michael Geiwitz with GRIP Molecular Technologies, Inc, General Graphene Corporation and support from National Science Foundation (NSF). Boston College Schiller Institute for Integrated Science and Society

MedTech Innovator is the world's largest Medtech accelerator. After a cut-throat competitive evaluation process with 1300+ applications, very few make it to the Pitch day and then to the accelerator program. I am excited to be a Judge at MedTech Innovator US accelerator program's pitch event today where 19 deeptech innovative Medtech companies present their products: 1. Akeyna - Karen Cronholm 2. Ansana - Dominique Surinx 3. Avance Innovation - Dr. Ankur Khajuria 4. BioSapien - Khatija A. 5. fluidIQ - Teresa Barnes 6. Global Vascular Co - Shunto Maegawa 7. GRIP Molecular Technologies, Inc - Edward Gillen 8. Impressio.tech - Amir Torbati 9. Inhibit Coatings - Eldon Tate 10. Neoflow Technologies Ltd - David Skorohod 11. NINA Medical - Shmuel Ben-Ezra 12. Novuson Surgical Inc. - Stuart Mitchell 13. Nurami Medical - Nora Nseir 14. PPS (Pressure Profile Systems) - Dr. Jae Son 15. Spiderwort Inc. - Charles M. Cuerrier 16. SpineX Inc. - Parag Gad 17. Trace Orthopedics - Adam Greenspan 18. VitalTrace - Arjun Kaushik 19. ZygoFix Ltd. - Ofer Levy Looking forward to learning more about the above innovative products and partnering with these intellectual founders and learning from them! Paul Grand, Brian Benson, Jerry Ciolino MedTech Innovator #medtech #startup #venturecapital #funding #accelerator #Medicaldevice #hardware #robotics #artificialintelligence #fundraising #angelinvesting

🌟 Breaking News from GRIP Molecular🌟 GRIP Molecular Technologies, Inc is proud to announce that our pioneering DIY at-home lab testing technology has been selected as one of the top 200 innovations from over 1,400 applications worldwide to present at the MedTech Innovator Road Tour 🔍 About the Road Tour: The MedTech Innovator Road Tour is part of the world's largest accelerator of medical technology. It consists of a series of high-stakes pitch events across the US and internationally, showcasing companies that stand out in the realms of medical devices, diagnostics, or digital health. 🚀 Why It Matters: The MedTech Innovator has a stellar track record of driving advancements in healthcare. With 612 portfolio companies, 304 FDA approvals, and $7.8B in follow-on funding, the accelerator is a powerhouse in actively transforming the healthcare system for better patient outcomes. GRIP Molecular Technologies, Inc is proud to be part of this prestigious event, sharing the stage with other innovators working towards the next generation of healthcare solutions. Stay tuned as GRIP continues to push the boundaries of what's possible in at home patient care! More info on MedTech Innovator Road Tour 2024: https://lnkd.in/gtrH7Ypi #MedTech #HealthTech #DigitalHealth #PatientCare #HealthcareInnovation

🌐 Big News from GRIP Molecular via 360Dx We’re excited to share that our innovative graphene biosensor assay testing technology for #infectiousdisease was covered by 360Dx who specializes in emerging economic and technological trends in the clinical diagnostic market. Full Article Here: https://t.ly/rwT8L Here is a quick summary ... Innovative Testing Approach: Biosensor cartridges, powered simply by a wireless charging-enabled cell phone, provide rapid and accurate results using only a swab sample. Collaboration Success: In partnership with Molecular Testing Labs, completed a clinical feasibility study for our COVID-19 test, achieving a 90% correlation with PCR results. Founder’s Vision: Bruce Batten, founder and CSO, emphasizes the accuracy and sensitivity of our saliva-based test for detecting the SARS-CoV-2 virus spike protein. Expanding Test Range: Launching with a multiplex test to differentiate COVID-19, flu, #RSV, and common cold viruses. Plans to include biomarkers for additional respiratory infections, #streptococcus, and #sepsis. Unique Technology: Hexagonal cartridges use graphene field-effect transistor (GFET) biosensors to detect up to 32 analytes, delivering results in just five minutes. User-Friendly Design: The test begins with a swab sample, and results are transferred via near-field communication to an app for easy reading and sharing with #healthcare providers. Aiming to make tests available through retail pharmacies, targeting household caregivers, with an anticipated retail price of around $40 per panel. Competitors: GrapheneDx and Qorvo Biotechnologies. Long-Term Vision: The potential of technology extends beyond infectious diseases, with applications in cardiac health, kidney function, concussion evaluation, and more. Read the full 360Dx article for a comprehensive overview of GRIP Molecular journey and vision: https://t.ly/rwT8L #GRIPMolecular #360Dx #HealthTech #Biotech #Innovation #HomeTesting #iot

Continued progress!

🚨𝐆𝐫𝐢𝐩 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐢𝐬 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐚 2027 𝐫𝐞𝐥𝐞𝐚𝐬𝐞 𝐟𝐨𝐫 𝐡𝐨𝐦𝐞-𝐛𝐚𝐬𝐞𝐝 𝐠𝐫𝐚𝐩𝐡𝐞𝐧𝐞 𝐛𝐢𝐨𝐬𝐞𝐧𝐬𝐨𝐫 𝐚𝐬𝐬𝐚𝐲𝐬🚨... 🧪GRIP Molecular Technologies, Inc, a testing start-up, is set to revolutionize home-based #infectiousdisease tests. Their biosensor cartridges, powered by wireless charging from a cell phone, provide rapid results for molecular targets or proteins with just a swab sample. In collaboration with Molecular Testing Labs, GRIP Molecular Technologies, Inc #covid19 test showed a 90% correlation with PCR results in a recent clinical feasibility study. Founder Bruce Batten is confident in the accuracy of GRIP Molecular Technologies, Inc saliva-based test, targeting the SARS-CoV-2 virus spike protein. The company aims for a 2027 market debut with a multiplex syndromic test differentiating covid19, flu A/B, respiratory syncytial virus, and common cold viruses. Grip plans to expand its biomarkers to include respiratory infections, streptococcus, and #sepsis. Using wireless charging, the assay runs on a phone-held cartridge, setting it apart from 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫𝐬 like GrapheneDx and Qorvo Biotechnologies. Zomedica, a veterinary health firm, acquired Qorvo Biotechnologies' subsidiary, redirecting focus to veterinary products. 𝐀𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 contribute to advancing biosensor-based tests and target identification methods. #IVD #biotech #lifesciences 🔗Source: https://lnkd.in/eXFZA_GH.

"GRIP's biosensor technology has the potential to establish a new healthcare norm. User-administered diagnostic testing in the home, telehealth interaction, data-informed diagnosis, and the prompt application of appropriate care -with no need for a visit to the clinic ..." GRIP has scientific and clinical evidence that this vision of the future is not just a dream, but instead a plausible reality ... Join CEO Edward Gillen as he walks us through some of the latest developments at GRIP Molecular Technologies (Video 7:53) #healthcare #medtech #medicaldevices #biotechnology #healthtech